Delivery Order SPE2DB22D9239-SPE2DB24FDM10

Award Date 8/28/24
Potential Completion Date 9/19/24
Potential Value $25K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $33,942.56 firm fixed-price delivery order is for the supply of KADCYLA 160 MG vials, with a completion date of July 25, 2025. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,405.54 firm fixed-price delivery order is for the supply of KADCYLA 100 MG VIALS, a specialized oncology medication. This award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. The IDC, valid through...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,915.24 firm fixed-price delivery order contract is for the provision of KADCYLA 100 MG VIALS, a specialized oncology medication. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. The...
This federal contract award, with ID SPE2DB22D9239|SPE2DB24FDJ06, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $20,478.24 firm fixed-price delivery order is for the supply of KADCYLA 100 MG VIALS, with a period of performance through May 13, 2024. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $7,679.34 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of KADCYLA 100 MG VIALS and has an ultimate completion date of August 19, 2024. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a wide range of pharmaceutical products and medical supplies to the Department of Defense...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,485.66 firm fixed-price delivery order is for the supply of 160 mg vials of the drug Kadcyla. This award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) under the DLA's SPE2DB program, which enables the agency to issue delivery orders for a comprehensive range of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $16,971.28 firm fixed-price delivery order is for the supply of 160 mg vials of the drug KADCYLA. The award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC enables the DLA to issue delivery orders...
This federal contract award, valued at $10,610.16, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of KADCYLA 100 MG VIALS, a specialized pharmaceutical product. The contract is not associated with a set-aside designation, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to...
The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $26,654.84, is for the delivery of KADCYLA 160 MG vials. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA, which runs through December 31, 2025. The IDC...
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $39,982.26 contract, awarded on April 18, 2024, is for the delivery of KADCYLA 160 MG vials by May 9, 2024. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) with DMS Pharmaceutical Group valued up to $499,999,999, which allows the DLA to issue orders for a...
  • SPE2DB22D9239
    Indefinite Delivery Contract
  • SPE2DB22D9239-SPE2DB24FDM10
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $24,623.52 firm fixed-price delivery order covers the supply of KADCYLA 160 MG VIALS, a specialty oncology medication. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the SPE2DB program, which enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical products to support the medical supply needs of Department of Defense healthcare facilities worldwide. This IDC, which runs through December 31, 2025, allows DMS Pharmaceutical Group to serve as a key supplier in the federal pharmaceutical supply chain, providing both routine and specialized drugs and medical supplies to military health facilities globally. The contract award does not have a set-aside designation.

Generated 11/27/24, 9:32 AM